ATE145556T1 - Verwendung von interleukin-4 zur behandlung der festen tumoren - Google Patents

Verwendung von interleukin-4 zur behandlung der festen tumoren

Info

Publication number
ATE145556T1
ATE145556T1 AT91918403T AT91918403T ATE145556T1 AT E145556 T1 ATE145556 T1 AT E145556T1 AT 91918403 T AT91918403 T AT 91918403T AT 91918403 T AT91918403 T AT 91918403T AT E145556 T1 ATE145556 T1 AT E145556T1
Authority
AT
Austria
Prior art keywords
pct
solid tumors
interleukin
date mar
treat solid
Prior art date
Application number
AT91918403T
Other languages
English (en)
Inventor
Marian L Plunkett
Joseph J Catino
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE145556T1 publication Critical patent/ATE145556T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2026IL-4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT91918403T 1990-09-06 1991-09-03 Verwendung von interleukin-4 zur behandlung der festen tumoren ATE145556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57896890A 1990-09-06 1990-09-06

Publications (1)

Publication Number Publication Date
ATE145556T1 true ATE145556T1 (de) 1996-12-15

Family

ID=24315064

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918403T ATE145556T1 (de) 1990-09-06 1991-09-03 Verwendung von interleukin-4 zur behandlung der festen tumoren

Country Status (12)

Country Link
US (1) US5382427A (de)
EP (1) EP0552243B1 (de)
JP (1) JPH06501017A (de)
KR (1) KR100229974B1 (de)
AT (1) ATE145556T1 (de)
AU (1) AU661979B2 (de)
CA (1) CA2091170A1 (de)
DE (1) DE69123361T2 (de)
DK (1) DK0552243T3 (de)
GR (1) GR3022321T3 (de)
HU (1) HU215389B (de)
WO (1) WO1992004044A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490006B1 (de) * 1990-12-13 1994-06-22 Schering-Plough Pharmazeutische Zusammensetzungen zur Behandlung von bösartigen B-Zellenkrankheiten
US5679338A (en) * 1994-05-12 1997-10-21 Osteoarthritis Science, Inc. Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
WO1996029394A1 (en) * 1995-03-17 1996-09-26 The Regents Of The University Of California Method for treating tumors
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
RU2115429C1 (ru) * 1997-07-22 1998-07-20 Закрытое акционерное общество "Фосфосорб" Рекомбинантный иммунотоксин на основе дифтерийного токсина и интерлейкина-2 (дт 482-il2) и способ его получения
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
ES2533255T3 (es) * 1998-07-13 2015-04-08 Board Of Regents, The University Of Texas System Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer
WO2000002587A1 (en) * 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
CA2447360A1 (en) * 2001-05-09 2002-11-14 Alk-Abello A/S Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
EP4285913A1 (de) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Hochwirksame adoptive t-zelltherapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3882611T2 (de) * 1987-08-03 1993-12-23 Tasuku Honjo Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten.
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria

Also Published As

Publication number Publication date
EP0552243B1 (de) 1996-11-27
AU661979B2 (en) 1995-08-17
KR100229974B1 (ko) 1999-11-15
WO1992004044A1 (en) 1992-03-19
HUT63769A (en) 1993-10-28
DE69123361T2 (de) 1997-04-30
CA2091170A1 (en) 1992-03-07
EP0552243A1 (de) 1993-07-28
US5382427A (en) 1995-01-17
HU9300624D0 (en) 1993-05-28
AU8850591A (en) 1992-03-30
DE69123361D1 (de) 1997-01-09
DK0552243T3 (da) 1997-03-10
GR3022321T3 (en) 1997-04-30
HU215389B (hu) 1998-12-28
JPH06501017A (ja) 1994-01-27

Similar Documents

Publication Publication Date Title
ATE145556T1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
ATE139447T1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE59407413D1 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
ATE143260T1 (de) Verwendung von (s)-isofluran und (s)-desfluran zur anästhesie sowie entsprechende arzneimittelzubereitungen
DK471386D0 (da) Farmaceutisk komposition til behandling af leukopeni
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
DE59407414D1 (de) Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
DE69021257D1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ATE289823T1 (de) Erhöhung der migration oder proliferation von keratinocyten
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE225183T1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
DE3881703D1 (de) Behandlung zur verbesserung der eigenschaften von keratintextilmaterialien.
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
DE69117974D1 (de) Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen
DE59407412D1 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
DE3786442D1 (de) Verwendung von follikelreifungshormon zur herstellung eines therapeutischen mittels zur behandlung von neoplasmen von gonadalem ursprung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee